表紙
市場調查報告書

CRO (臨床研究委外機構)的全球市場預測 2023年:藥物研發研究、CMC (化學,製造,品管)、前臨床服務、臨床研究服務、化驗服務

Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023

出版商 MarketsandMarkets 商品編碼 379870
出版日期 內容資訊 英文 262 Pages
訂單完成後即時交付
價格
Back to Top
CRO (臨床研究委外機構)的全球市場預測 2023年:藥物研發研究、CMC (化學,製造,品管)、前臨床服務、臨床研究服務、化驗服務 Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2023
出版日期: 2018年02月02日內容資訊: 英文 262 Pages
簡介

全球CRO (臨床研究委外機構) 服務市場規模,預計從2018年的391億3,000萬美元到2023年達563億4,000萬美元,以7.9%的年複合成長率擴大。該市場的成長主要是由於R&D活動的外包的增加,及臨床試驗數的增加。可是,CRO服務市場上競爭激烈,成為對該市場活動的企業來說的大課題之一。。

本報告以全球CRO (臨床研究委外機構) 市場為研究主題,提供市場概要,市場發展促進、阻礙因素,市場上課題及機會,各類型、治療領域、終端用戶、地區市場現況與展望相關調查分析,競爭環境,主要企業簡介,為您概述為以下內容。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • CRO服務市場概要
  • 亞太地區:CRO服務市場,各種類、各國
  • CRO服務市場:地區的成長機會
  • CRO服務市場:地區混合
  • CRO服務市場:新興 vs. 先進各國

第5章 市場概要

  • 簡介
  • 市場動態
    • 市場成長的促進要素
    • 市場機會
    • 市場課題
  • 產業趨勢
    • CRO產業上整合的增加
    • 新興市場的臨床試驗的外包增加
    • 新技術的引進

第6章 CRO服務市場:各類型

  • 簡介
  • 臨床研究服務
    • 階段I臨床研究服務
    • 階段II臨床研究服務
    • 階段III臨床研究服務
    • 階段IV臨床研究服務
  • 早期開發服務
    • 藥物研發研究
    • CMC (化學,製造,品管)
    • 前臨床服務
  • 化驗服務
    • 生物分析實驗服務
    • 分析實驗服務
  • 諮詢服務

第7章 全球CRO服務市場:各治療領域

  • 簡介
  • 癌症
  • 感染疾病
  • 中樞神經系統 (CNS) 疾病
  • 免疫疾病
  • 心血管疾病
  • 呼吸疾病
  • 糖尿病
  • 其他治療領域

第8章 CRO服務市場:各終端用戶

  • 簡介
  • 醫藥品、生物醫藥品企業
  • 醫療設備企業
  • 大學機關

第9章 CRO服務市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第10章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭情形

第11章 企業簡介

  • IQVIA
  • LABCORP
  • PAREXEL
  • PRA HEALTH SCIENCES
  • PPD
  • ICON PLC
  • SYNEOS HEALTH
  • WUXI PHARMATECH
  • CHARLES RIVER
  • MEDPACE HOLDINGS
  • SGS
  • ENVIGO
  • MPI RESEARCH

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PH 4672

"The Contract Research Organization (CRO) services market is projected to grow at a CAGR of 7.6% between 2018 and 2023."

The CRO services market is expected to reach USD 56.34 billion by 2023 from USD 39.13 billion in 2018, at a CAGR of 7.6%. Increased outsourcing of R&D activities and increasing number of clinical trials are some of the major factors driving the growth of this market. However, intense competition in the CRO services market is one of the major challenges for the players operating in the CRO services market.

"Laboratory services segment to witness the highest growth rate during the forecast period."

Among the CRO services, the laboratory services segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the increasing number of pipeline drugs and growing outsourcing of laboratory services by pharmaceutical and biopharmaceutical companies.

"Oncology segment to grow at the highest CAGR from 2018 to 2023."

Oncology segment is expected to register the highest CAGR during the forecast period. The increasing number of clinical trials and rising prevalence of cancer worldwide are the major factors supporting its growth during the forecast period.

"APAC to witness the highest growth rate during the forecast period."

The Asia Pacific region is expected to witness the highest CAGR during the forecast period, owing the rapid growth in the pharmaceutical and biopharmaceutical industry, low cost of clinical trials, rising number of CROs, and favorable government policies in the region.

Break primary participants:

  • By Company Type - Tier 1: 21%, Tier 2-26%, and Tier 3-53%
  • By Designation - C Level: 32%, Director Level: 26%, and Others: 42%
  • By Region - North America: 26%, Europe: 35%, Asia Pacific: 20%, Latin America: 11%, and the Middle East & Africa: 8%

Research Coverage:

The report analyzes the various CRO services and their adoption patterns in the market. It aims at estimating the market size and future growth potential of the global CRO services market for different segments such as type, therapeutic area, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use any one or combination of the below-mentioned strategies for strengthening their market positions.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the service portfolios offered by the top players in the CRO services market
  • Service Launch/Innovation: Detailed insights on new service launches in the CRO services market
  • Market Development: Comprehensive information about lucrative emerging markets, by type, therapeutic area, end user, and region
  • Market Diversification: Exhaustive information about new services, growing geographies, recent developments in the CRO services market
  • Competitive Assessment: In-depth assessment of growth strategies, services, and manufacturing capabilities of leading players in the CRO services market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
    • 2.2.1. BOTTOM-UP APPROACH
    • 2.2.2. TOP-DOWN APPROACH
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. CRO SERVICES MARKET OVERVIEW
  • 4.2. ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE AND COUNTRY
  • 4.3. CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4. CRO SERVICES MARKET: GEOGRAPHIC MIX
  • 4.5. CRO SERVICES MARKET: DEVELOPING VS. DEVELOPED COUNTRIES

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Growing R&D expenditure
      • 5.2.1.2. Increased outsourcing of R&D activities
      • 5.2.1.3. Increasing number of clinical trials
    • 5.2.2. OPPORTUNITIES
      • 5.2.2.1. Growth in the biosimilars and biologics markets
      • 5.2.2.2. Rising demand for specialized testing services
      • 5.2.2.3. Emerging Asian markets
    • 5.2.3. CHALLENGES
      • 5.2.3.1. Intense competition in the cro services market
      • 5.2.3.2. Shortage of skilled professionals
  • 5.3. INDUSTRY TRENDS
    • 5.3.1. GROWING CONSOLIDATION IN THE CRO INDUSTRY
    • 5.3.2. INCREASING OUTSOURCING OF CLINICAL TRIALS TO EMERGING MARKETS
    • 5.3.3. ADOPTION OF NEW TECHNOLOGIES

6. CRO SERVICES MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. CLINICAL RESEARCH SERVICES
    • 6.2.1. PHASE I CLINICAL RESEARCH SERVICES
    • 6.2.2. PHASE II CLINICAL RESEARCH SERVICES
    • 6.2.3. PHASE III CLINICAL RESEARCH SERVICES
    • 6.2.4. PHASE IV CLINICAL RESEARCH SERVICES
  • 6.3. EARLY-PHASE DEVELOPMENT SERVICES
    • 6.3.1. DISCOVERY STUDIES
    • 6.3.2. CHEMISTRY, MANUFACTURING, & CONTROL (CMC)
    • 6.3.3. PRECLINICAL SERVICES
      • 6.3.3.1. Pharmacokinetics/pharmacodynamics (PK/PD)
      • 6.3.3.2. Toxicology testing services
      • 6.3.3.3. Other preclinical services
  • 6.4. LABORATORY SERVICES
    • 6.4.1. BIOANALYTICAL TESTING SERVICES
    • 6.4.2. ANALYTICAL TESTING SERVICES
      • 6.4.2.1. Physical characterization
      • 6.4.2.2. Raw material testing
      • 6.4.2.3. Batch-release testing
      • 6.4.2.4. Stability testing
      • 6.4.2.5. Other analytical testing services
  • 6.5. CONSULTING SERVICES

7. GLOBAL CRO SERVICES MARKET, BY THERAPEUTIC AREA

  • 7.1. INTRODUCTION
  • 7.2. ONCOLOGY
  • 7.3. INFECTIOUS DISEASES
  • 7.4. CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
  • 7.5. IMMUNOLOGICAL DISORDERS
  • 7.6. CARDIOVASCULAR DISEASES
  • 7.7. RESPIRATORY DISORDERS
  • 7.8. DIABETES
  • 7.9. OTHER THERAPEUTIC AREAS

8. CRO SERVICES MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 8.3. MEDICAL DEVICE COMPANIES
  • 8.4. ACADEMIC INSTITUTES

9. CRO SERVICES MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. UK
    • 9.3.3. FRANCE
    • 9.3.4. ITALY
    • 9.3.5. SPAIN
    • 9.3.6. REST OF EUROPE
  • 9.4. ASIA PACIFIC
    • 9.4.1. CHINA
    • 9.4.2. JAPAN
    • 9.4.3. INDIA
    • 9.4.4. REST OF ASIA PACIFIC
  • 9.5. LATIN AMERICA
  • 9.6. MIDDLE EAST & AFRICA

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. COMPETITIVE SCENARIO
    • 10.3.1. AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS (2014-2017)
    • 10.3.2. SERVICE LAUNCHES (2014-2017)
    • 10.3.3. EXPANSIONS (2014-2017)
    • 10.3.4. ACQUISITIONS (2014-2017)

11. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View)*

  • 11.1. IQVIA
  • 11.2. LABCORP
  • 11.3. PAREXEL
  • 11.4. PRA HEALTH SCIENCES
  • 11.5. PPD
  • 11.6. ICON PLC
  • 11.7. SYNEOS HEALTH
  • 11.8. WUXI PHARMATECH
  • 11.9. CHARLES RIVER
  • 11.10. MEDPACE HOLDINGS
  • 11.11. SGS
  • 11.12. ENVIGO
  • 11.13. MPI RESEARCH

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS OF INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.5. AVAILABLE CUSTOMIZATIONS
  • 12.6. RELATED REPORTS
  • 12.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
  • TABLE 2: R&D EXPENDITURE & PERCENTAGE CHANGE, BY PHARMACEUTICAL COMPANY (2014-2016)
  • TABLE 3: INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH
  • TABLE 4: LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS IN THE US, 2016
  • TABLE 5: CLINICAL STUDIES FOR BIOLOGIC & BIOSIMILAR MOLECULES (2017)
  • TABLE 6: GROWING BIOSIMILARS AND BIOLOGICS MARKETS TO PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES
  • TABLE 7: INTENSE COMPETITION IN THE CRO SERVICES MARKET IS A MAJOR CHALLENGE IN THE MARKET
  • TABLE 8: MAJOR MERGERS AND ACQUISITIONS IN CRO INDUSTRY (2013-2017)
  • TABLE 9: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 10: CRO SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 11: NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION, 2017
  • TABLE 12: KEY CLINICAL RESEARCH SERVICES OFFERED BY PROMINENT PLAYERS
  • TABLE 13: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 14: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 15: COMPLETED PHASE II STUDIES FOR DIFFERENT THERAPEUTIC AREAS
  • TABLE 16: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: COMPLETED PHASE II STUDIES FOR DIFFERENT THERAPEUTIC AREAS
  • TABLE 18: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 19: COMPLETED PHASE III STUDIES FOR DIFFERENT THERAPEUTIC AREAS
  • TABLE 20: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 21: COMPLETED PHASE IV STUDIES FOR DIFFERENT THERAPEUTIC AREAS
  • TABLE 22: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 23: KEY EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY PROMINENT PLAYERS
  • TABLE 24: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 25: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 26: DISCOVERY STUDIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 27: CHEMISTRY, MANUFACTURING, & CONTROL MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 28: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 29: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 30: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 31: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 32: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 33: LABORATORY SERVICES: KEY SERVICES OFFERED BY PROMINENT PLAYERS
  • TABLE 34: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 35: LABORATORY SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 36: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 37: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 38: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 39: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 40: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 41: BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 42: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 43: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 44: CONSULTING SERVICES: KEY SERVICES OFFERED BY PROMINENT PLAYERS
  • TABLE 45: CONSULTING SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 46: GLOBAL NUMBER OF CLINICAL TRIALS IN DIFFERENT THERAPEUTIC AREAS, 2017
  • TABLE 47: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 48: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 49: LIST OF PIPELINE DRUGS FOR INFECTIOUS DISEASES (2016)
  • TABLE 50: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 51: LIST OF PIPELINE DRUGS FOR CNS DISORDERS (2016)
  • TABLE 52: CRO SERVICES MARKET FOR CNS DISORDERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 53: PREVALENCE OF PID, BY REGION, 2013 VS. 2015
  • TABLE 54: LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2016)
  • TABLE 55: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 56: LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2016)
  • TABLE 57: CRO SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 58: LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS (2016)
  • TABLE 59: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 60: LIST OF PIPELINE DRUGS FOR DIABETES (2016)
  • TABLE 61: CRO SERVICES MARKET FOR DIABETES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 62: LIST OF PIPELINE DRUGS FOR OTHER THERAPEUTIC AREAS (2016)
  • TABLE 63: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY/REGION, 2016-2023 (USD MILLION)
  • TABLE 64: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 65: NUMBER OF BIOPHARMACEUTICAL DRUGS IN DEVELOPMENT ACROSS THE GLOBE, 2016
  • TABLE 66: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 67: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 68: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 69: CRO SERVICES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 70: NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 71: NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 72: NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 73: NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 74: NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 75: NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 76: NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 77: NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 78: NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 79: TOTAL NUMBER OF CLINICAL TRIALS IN THE US (2017)
  • TABLE 80: US: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 81: US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 82: US: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 83: US: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 84: US: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 85: US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 86: US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 87: US: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 88: CANADA: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 89: CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 90: CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 91: CANADA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 92: CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 93: CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 94: CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 95: CANADA: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 96: EUROPE: PHARMACEUTICAL R&D EXPENDITURE, BY COUNTRY, 2012 VS. 2014
  • TABLE 97: EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 98: EUROPE: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 99: EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 100: EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 101: EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 102: EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 103: EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 104: EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 105: EUROPE: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 106: GERMANY: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 107: GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 108: GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 109: GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 110: GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 111: GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 112: GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 113: GERMANY: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 114: UK: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 115: UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 116: UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 117: UK: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 118: UK: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 119: UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 120: UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 121: UK: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 122: FRANCE: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 123: FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 124: FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 125: FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 126: FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 127: FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 128: FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 129: FRANCE: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 130: CLINICAL TRIALS IN ITALY (2013 VS. 2014)
  • TABLE 131: ITALY: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 132: ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 133: ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 134: ITALY: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 135: ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 136: ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 137: ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 138: ITALY: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 139: SPAIN: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 140: SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 141: SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 142: SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 143: SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 144: SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 145: SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 146: SPAIN: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 147: PHARMACEUTICAL R&D EXPENDITURE & PRODUCTION IN ROE COUNTRIES (2012 VS. 2014)
  • TABLE 148: ROE: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 149: ROE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 150: ROE: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 151: ROE: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 152: ROE: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 153: ROE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 154: ROE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 155: ROE: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 156: TOTAL NUMBER OF CLINICAL TRIALS IN ASIA PACIFIC, BY THERAPEUTIC AREA, 2017
  • TABLE 157: ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 158: ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 159: ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 160: ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 161: ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 162: ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 163: ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 164: ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 165: ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 166: TOTAL NUMBER OF CLINICAL TRIALS IN CHINA, BY THERAPEUTIC AREA, 2017
  • TABLE 167: CHINA: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 168: CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 169: CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 170: CHINA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 171: CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 172: CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 173: CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 174: CHINA: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 175: JAPAN: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 176: JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 177: JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 178: JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 179: JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 180: JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 181: JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 182: JAPAN: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 183: TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017
  • TABLE 184: INCREASE IN R&D EXPENDITURE OF TOP 5 INDIAN PHARMACEUTICAL COMPANIES (2010 VS. 2017)
  • TABLE 185: INDIA: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 186: INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 187: INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 188: INDIA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 189: INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 190: INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 191: INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 192: INDIA: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 193: TOTAL NUMBER OF CLINICAL TRIALS IN AUSTRALIA, SINGAPORE, & MALAYSIA, BY THERAPEUTIC AREA, 2017
  • TABLE 194: ROAPAC: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 195: ROAPAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 196: ROAPAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 197: ROAPAC: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 198: ROAPAC: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 199: ROAPAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 200: ROAPAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 201: ROAPAC: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 202: TOTAL NUMBER OF CLINICAL TRIALS IN LATIN AMERICA, BY THERAPEUTIC AREA, 2017
  • TABLE 203: LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 204: LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 205: LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 206: LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 207: LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 208: LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 209: LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 210: LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 211: TOTAL NUMBER OF CLINICAL TRIALS IN THE MIDDLE EAST AND AFRICA, BY THERAPEUTIC AREA, 2017
  • TABLE 212: MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 213: MIDDLE EAST AND AFRICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 214: MIDDLE EAST AND AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 215: MIDDLE EAST AND AFRICA: CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 216: MIDDLE EAST AND AFRICA: LABORATORY SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 217: MIDDLE EAST AND AFRICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 218: MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2023 (USD MILLION)
  • TABLE 219: MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 220: GROWTH STRATEGY MATRIX (2014-2017)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DATA TRIANGULATION METHODOLOGY
  • FIGURE 4: CRO SERVICES MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 5: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018 VS. 2023 (USD BILLION)
  • FIGURE 6: CRO SERVICES MARKET, BY END USER, 2018 VS. 2023 (USD BILLION)
  • FIGURE 7: GEOGRAPHIC SNAPSHOT: CRO SERVICES MARKET
  • FIGURE 8: GROWING R&D EXPENDITURE AND INCREASE IN NUMBER OF CLINICAL TRIALS TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 9: PHASE III SEGMENT WILL CONTINUE TO DOMINATE APAC CLINICAL RESEARCH SERVICES MARKET DURING THE FORECAST PERIOD
  • FIGURE 10: THE US DOMINATED THE CRO SERVICES MARKET IN 2017
  • FIGURE 11: NORTH AMERICA TO DOMINATE THE CRO SERVICES MARKET DURING THE FORECAST PERIOD
  • FIGURE 12: CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 13: CONTRACT RESEARCH ORGANIZATION (CRO) SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14: NUMBER OF NEW CHEMICAL OR BIOLOGICAL ENTITIES (1997-2016)
  • FIGURE 15: TOTAL NUMBER OF REGISTERED STUDIES (2005-2017)
  • FIGURE 16: TOTAL NUMBER OF NEW MOLECULAR ENTITY (NME) AND NEW BIOLOGIC LICENSE APPLICATION (BLA) FILINGS AND APPROVALS IN THE US, 2006-2015
  • FIGURE 17: KEY TRENDS IN THE CRO SERVICES MARKET
  • FIGURE 18: CLINICAL RESEARCH SERVICES SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL CRO SERVICES MARKET BY 2023
  • FIGURE 19: COMPARATIVE ANALYSIS OF CLINICAL TRIALS OVER THE YEARS (2010-2016)
  • FIGURE 20: BIOPHARMACEUTICAL DRUGS UNDER DEVELOPMENT, BY THERAPEUTIC AREA, 2016
  • FIGURE 21: PHASES OF DRUG DISCOVERY STUDIES
  • FIGURE 22: ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL CRO SERVICES MARKET BY 2023
  • FIGURE 23: WORLDWIDE CANCER INCIDENCE AND MORTALITY (2012-2025)
  • FIGURE 24: TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY (2017)
  • FIGURE 25: DIABETES PREVALENCE, BY COUNTRY, 2015 (MILLION INDIVIDUALS)
  • FIGURE 26: PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO DOMINATE THE CRO SERVICES MARKET DURING THE FORECAST PERIOD
  • FIGURE 27: R&D SPENDING OF PHRMA MEMBER COMPANIES, 1980-2015
  • FIGURE 28: CLINICAL STUDIES FOR MEDICAL DEVICES (2017)
  • FIGURE 29: CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 30: TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA (2017)
  • FIGURE 31: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 32: PHARMACEUTICAL R&D EXPENDITURE IN THE US (1990-2014)
  • FIGURE 33: EUROPE: MARKET SNAPSHOT
  • FIGURE 34: ASIA PACIFIC: MARKET SNAPSHOT
  • FIGURE 35: KEY DEVELOPMENTS IN THE CRO SERVICES MARKET, 2014-2017
  • FIGURE 36: GLOBAL CRO SERVICES MARKET SHARE, BY KEY PLAYER, 2017
  • FIGURE 37: IQVIA: COMPANY SNAPSHOT
  • FIGURE 38: LABCORP: COMPANY SNAPSHOT
  • FIGURE 39: PAREXEL: COMPANY SNAPSHOT
  • FIGURE 40: PRA HEALTH SCIENCES: COMPANY SNAPSHOT
  • FIGURE 41: ICON PLC: COMPANY SNAPSHOT
  • FIGURE 42: INC RESEARCH HOLDINGS: COMPANY SNAPSHOT
  • FIGURE 43: WUXI PHARMATECH: COMPANY SNAPSHOT
  • FIGURE 44: CHARLES RIVER: COMPANY SNAPSHOT (2016)
  • FIGURE 45: MEDPACE HOLDINGS: COMPANY SNAPSHOT
  • FIGURE 46: SGS: COMPANY SNAPSHOT
Back to Top